Nasus Pharma Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NSRX research report →
Range $22 – $22
Price Chart
About the company
Nasus Pharma Ltd. , a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
- CEO
- Brendan O'Grady
- IPO
- 2025
- Employees
- 7
- HQ
- Tel Aviv, TA, IL
Get TickerSpark's AI analysis on NSRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.72M
- P/E
- -2.23
- Fwd P/E
- 3.12
- PEG
- 0.02
- P/S
- 0.00
- P/B
- 2.31
- EV/EBITDA
- -1.67
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -158.83%
- ROIC
- -96.46%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-4,904,000
- Net Income
- $-5,856,000-282.2%
- EPS
- $-0.72-323.5%
- OCF Growth
- -639.5%
- FCF Growth
- -641.7%
- 52W High
- $9.50
- 52W Low
- $1.98
- 50D MA
- $3.27
- 200D MA
- $3.39
- Beta
- 4.26
- RSI (14)
- 27
- Avg Volume
- 16.80K
No earnings-call transcripts are available for NSRX yet.
- Free Float
- 33.1%
- Shares Outstanding
- 8.61M
- Float Shares
- 2.85M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 11, 28 | Sassi Nir | other | 0 |
| Nov 11, 27 | Sassi Nir | other | 0 |
| Feb 11, 28 | Sassi Nir | other | 0 |
| Oct 8, 26 | O'Grady Brendan P. | other | 210,000 |
| Jan 17, 25 | Elmaliah Oren | other | 0 |
| Jun 13, 20 | Elmaliah Oren | other | 0 |
| Sep 18, 26 | Rubin Eyal | other | 0 |
| Jul 27, 26 | O'Grady Brendan P. | other | 0 |
| Jul 22, 26 | Teleman Dan Benjamin | other | 0 |
| Jun 17, 26 | Teleman Dan Benjamin | buy | 6,550 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NSRX coverage
Recent articles, reports, and earnings notes.
No research on NSRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NSRX report →Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion
globenewswire.com · Nov 17
Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
globenewswire.com · Nov 16
Nasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026
globenewswire.com · Nov 10
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
globenewswire.com · Sep 29
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
globenewswire.com · Sep 14
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 8
Nasus Pharma Announces Transition of Chief Financial Officer
globenewswire.com · Aug 19
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.